Last Update: Jul 06, 2026 A Post Marketing Surveillance on PluvictoTM (Lutetium(177Lu) Vipivotide Tetraxetan) in South Korea; An Open-label, Non-interventional, Primary Data Collection, Multi-center, Non-comparative, Non-randomized Observational Study to Assess Safety and Effectiveness of Pluvicto in Real World Setting ClinicalTrials.gov Identifier: [NCT06514521](https://clinicaltrials.gov/ct2/show/NCT06514521) Novartis Reference Number:CAAA617A1KR01 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description Post marketing study on Pluvicto in Korea This is open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Pluvicto in patients with mCRPC in the real-world setting in South Korea. Condition Metastatic Castration-resistant Prostate Cancer Overall Status Recruiting Number of Participants278 Start Date Apr 18, 2025 Completion Date May 31, 2028 Gender Male Age(s) 18 Years - 100 Years (Adult, Older Adult) ## Interventions Other ### Lutetium vipivotide tetraxetan This is an observational study. There is no treatment allocation. The decision to initiate Lutetium vipivotide tetraxetan will be based solely on clinical judgement. ## Eligibility Criteria Inclusion criteria Study participants eligible for inclusion in this study must meet all of the following criteria: 1\. Male adult patient age ≥ 18 2\. Subject who are being treated with Pluvicto or whose treatment plan is finalized and scheduled to be administered at the time of consent by physician in accordance with the approved indication in South Korea 3\. Subject who provided the written informed consent prior to the study enrollment Exclusion criteria Study participants meeting any of the following criteria are not eligible for inclusion in this study: 1\. Subject whose medical record is not accessible 2\. Subject who is not willing to provide the informed consent South Korea #### Novartis Investigative Site Recruiting Seongnam-si,Gyeonggi-do,13620,South Korea #### Novartis Investigative Site Recruiting Gyeonggi-do,Korea,10408,South Korea #### Novartis Investigative Site Recruiting Seoul,Seoul,06351,South Korea #### Novartis Investigative Site Recruiting Seoul,03722,South Korea #### Novartis Investigative Site Recruiting Seoul,05505,South Korea #### Novartis Investigative Site Recruiting Seoul,06591,South Korea #### Novartis Investigative Site Recruiting Seoul,110-744,South Korea #### Novartis Investigative Site Recruiting Suwon,Gyeonggi-do,442-723,South Korea #### Novartis Investigative Site Recruiting Busan,Korea,46033,South Korea #### Novartis Investigative Site Recruiting Seoul,Seoul,03374,South Korea #### Novartis Investigative Site Recruiting Seoul,01812,South Korea #### Novartis Investigative Site Recruiting Jeollanam,519763,South Korea ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: